Life Technologies Submits Sequencer and HLA Typing Kits to FDA for Diagnostic Use

*If cleared, Life’s 3500 Dx Genetic Analyzer and SeCore® HLA Sequencing kits would constitute the first 510(k)-cleared sequence-based test for HLA typing in the United States*

- Sequencing offers accurate high-resolution method for HLA typing
- SeCore® HLA would be the first 510(k)-cleared sequence-based typing solution
- 510(k)–cleared 3500 Dx would make sequencing accessible to hospital labs

CARLSBAD, Calif. – August 1, 2011 – Life Technologies Corporation today announced that it has submitted its 3500 Dx Genetic Analyzer and SeCore® HLA Sequencing System to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.

If cleared, the Applied Biosystems 3500 Dx / 3500xL Dx Genetic Analyzer CS2 and the Invitrogen SeCore® HLA Sequencing System would constitute the first 510(k)-cleared sequence-based test for HLA typing in the United States. HLA typing is one of the essential components of determining organ and bone marrow transplant compatibility between donors and patients.

“With clearance, transplant patients could be assured that their HLA typing was performed in a laboratory that utilizes a thoroughly tested, high resolution technique,” said Todd Laird, Vice President and General Manager of Life Technologies Fragment and Sequence Genomics Division. “High-resolution DNA matching for HLA-A, -B, -C, and -DRB1 alleles is associated with reduced risk of rejection or graft versus host disease.”

HLA typing on the 3500 Dx would offer labs an optimized, streamlined workflow with higher resolution than other molecular HLA typing technologies such as sequence-specific oligonucleotide probing (SSOP) methods. Sequence based typing is the only HLA typing method that results in the comprehensive nucleotide sequencing of the entire targeted exon. Other methods rely on probing only segments of the exon and using pattern matching methods to obtain typing results.

Clearance would make the 3500 Dx / 3500xL Dx Genetic Analyzer CS2 the only 510(k)-cleared Sanger Sequencer currently for sale on the market. Sanger sequencing is the technology that powered the Human Genome Project and remains the “gold-standard” for its accuracy, reliability and ease of use. The 3500 Dx instrument was designed with clinicians in mind, featuring a novel consumables design that incorporates the ability to track information with radio frequency identification (RFID) tags, new optical and thermal sub-systems, as well as redesigned data collection and analysis software, creating a cost-effective method for sample analyses.

“A 510(k)-cleared sequencing instrument would pave the way toward establishing genomic medicine as a mainstay of the clinical lab,” said Laird. “The 3500 Dx was designed to meet the hospital lab’s needs for reliability and user-friendly operation.”

It is also expected that clearance would facilitate additional assay development for the 3500 Dx. In May 2011, Life Technologies announced a partnership with Gen-Probe, Inc. for development of diagnostic assays for the platform, and continues to seek additional partners to develop the assay menu. The 3500 Dx
instrument is CE-marked for in vitro diagnostic use in Europe and is also available in Japan, Australia, India, New Zealand, Singapore, and Taiwan.

**About Life Technologies**

*Life Technologies Corporation* is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies’ industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: [http://www.lifetechnologies.com](http://www.lifetechnologies.com). Follow Life Technologies on Twitter [@LIFECorporation](https://twitter.com/LIFECorporation) and on [Facebook](https://www.facebook.com/LifeTechnologies).

**Life Technologies’ Safe Harbor Statement**

This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

**Life Technologies Contact**

Suzanne Clancy  
760-602-4545  
760-717-8294  
suzanne.clancy@lifetech.com